Abdul Abdirahman
Principal
F-Prime
Principal investing in early-stage B2B software, fintech, and vertical SaaS.
Bio
Professional summary
Alex Pasteur is a Partner at F-Prime Capital, based in London. He joined the firm in 2012 and focuses on therapeutics and life sciences. His official profile lists founding investor roles in ARTBIO, Tenpoint Therapeutics, and Orchard Therapeutics, as well as board roles at Nodthera, Genomics, Peptone, Shift Bioscience, Owkin, and Pulmocide, and a board observer role at Castor. Before F-Prime, he worked at MVM Life Science Partners in the U.S. and Europe and has worked in healthcare investing since 2001. He holds an MA in Natural Sciences and a PhD in Chemistry from Cambridge University.
Investment focus
Stage, sector, and overall fit
Stage
Life sciences venture investmentsCompany formation / founding investor opportunities in therapeutics
Sector
TherapeuticsLife sciencesBiotechnologyGenomicsComputational biology and drug discovery
Thesis
TherapeuticsLife sciences
Notable companies
Selected portfolio companies the partner has backed
ARTBIOTenpoint TherapeuticsOrchard TherapeuticsNodtheraGenomicsPeptoneShift BioscienceOwkinPulmocideCastorAcacia PharmaArvelle TherapeuticsAdaptimmune Therapeutics
How to approach
Framing and angles for outreach
Pitch framing
Lead with a therapeutics or life-sciences opportunity supported by strong science, differentiated platform biology or chemistry, and credible clinical translation.
Personalization hooks
- 1Reference his Cambridge scientific background and long healthcare investing track record.
- 2If relevant, connect to European life sciences or company-formation themes from ARTBIO, Tenpoint, and Orchard.
Recent signals
What the partner has said or done recently
Official profile lists recent or featured F-Prime impact content on ARTBIO, Orchard Therapeutics, and Peptone.
Background
Career, education, and skills
Career history
- F-Prime Capital PartnersPartnerOct 2012 - Present
- Tenpoint TherapeuticsNon Executive DirectorDec 2020 - Present
- NodTheraNon Executive DirectorFeb 2018 - Present
- Genomics LtdNon Executive DirectorJan 2018 - Present
- PeptoneNon Executive DirectorJun 2022 - Present
- MVM Life Science Partners LLPPartnerPre-2012
Education
- University of CambridgePhD, Chemistry1992-1996
- University of CambridgeMA, Natural Sciences1989-1992
Skills
BiopharmaceuticalsBiotechnology
Other partners at F-Prime
12 more profiles
AP
Anastasiya Sybirna, PhD
Senior Associate
F-Prime
Senior Associate on F-Prime's London healthcare investment team.
Bala Varadhan
Principal
F-Prime
Principal focused on early-stage crypto, blockchain and Web3 investments.
Benjamin Gorman
Principal
F-Prime
Principal investing in early-stage enterprise software and AI.
Betsy Mulé
Principal
F-Prime
Principal investing in enterprise technology and robotics.
Brett Cook
Partner
F-Prime
F-Prime Partner investing in healthcare technology and services companies.
Brian Yordy
Principal
F-Prime
Principal investing in biopharmaceutical and medical technology companies.
Carl Bradford Byers 🚑
Partner
F-Prime
F-Prime Partner and former athenahealth founding CFO investing in healthcare IT and digital health.
Carl Byers
Partner
F-Prime
Carl Byers is a Partner at F-Prime Capital with significant operating experience in healthcare IT, including as a founding team member and CFO of athenahealth.
Chance Mathisen
Associate
F-Prime
Associate focused on early-stage enterprise software investments.
Chong Xu
Partner
F-Prime
F-Prime partner focused on biopharma, medtech, company formation, and China healthcare opportunities.
Connie Li
Principal
F-Prime
Principal on F-Prime's life sciences team focused on biotechnology.